News coverage about Charles River Laboratories Intl. (NYSE:CRL) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Charles River Laboratories Intl. earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 47.0093862631582 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

CRL has been the topic of several recent research reports. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 price target on the stock in a research note on Friday, May 11th. TheStreet raised Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research note on Thursday, May 10th. KeyCorp raised Charles River Laboratories Intl. from a “sector weight” rating to an “overweight” rating and lifted their price target for the company from $115.85 to $130.00 in a research note on Friday, June 15th. Bank of America lifted their price target on Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Finally, Royal Bank of Canada raised Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price target on the stock in a research note on Tuesday, July 17th. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Charles River Laboratories Intl. presently has a consensus rating of “Buy” and a consensus price target of $125.40.

NYSE:CRL opened at $121.56 on Friday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.48 and a current ratio of 1.72. The stock has a market capitalization of $5.86 billion, a P/E ratio of 23.07, a P/E/G ratio of 1.53 and a beta of 0.66. Charles River Laboratories Intl. has a 52-week low of $96.70 and a 52-week high of $130.66.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Wednesday, August 8th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.16. The business had revenue of $585.30 million for the quarter, compared to the consensus estimate of $570.65 million. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. Charles River Laboratories Intl.’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.29 earnings per share. analysts anticipate that Charles River Laboratories Intl. will post 5.91 earnings per share for the current year.

In related news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $120.05, for a total value of $149,942.45. Following the sale, the insider now owns 13,690 shares of the company’s stock, valued at $1,643,484.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James C. Foster sold 5,005 shares of Charles River Laboratories Intl. stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $110.80, for a total value of $554,554.00. Following the completion of the sale, the chief executive officer now directly owns 296,676 shares in the company, valued at approximately $32,871,700.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,258 shares of company stock worth $4,001,244. 2.10% of the stock is owned by company insiders.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.